Fb704a (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03890302 (ClinicalTrials.gov) | March 14, 2019 | 25/3/2019 | Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A | A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A | Rheumatoid Arthritis | Drug: FB704A;Drug: Placebo | Fountain Biopharma Inc. | Oneness Biotech Co., Ltd. | Completed | 18 Years | 55 Years | All | 31 | Phase 1 | United States |